Skip to content
Screener
Emergent Biosolutions logo

Emergent Biosolutions

EBS

Emergent BioSolutions is a global life sciences company that develops and manufactures preparedness and response solutions for public health threats, including chemical, biological, and opioid-related crises.

Market cap
$326.1M-21.5%
Revenue$770.2M-9.6%
Net income-$134.2M-2.0%
Free cash flow$91.6M-43.9%
EPS (diluted)-$2.73-1.1%
Trailing twelve months · change vs. prior year

Earnings

Q2 2026 report

August 5, 2026
Revenue$234.3MBeat by $56.8MEPS$0.60Beat by $0.68

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$123.2M
EPS estimate-$0.37

Financials

Q2 2026

Income statement

See full
Revenue$234.3M+66.3%
Gross profit$137.2M+85.4%
Operating income-$125.1M-7,919%
Net income-$180.2M-1,402%
EPS (diluted)-$3.49-1,486%

Balance sheet

See full
Cash & equivalents$140.9M-48.0%
Total debt$588.2M-13.0%
Total equity$341.4M-36.3%
Total assets$1.1B-21.2%

Cash flow

See full
Operating cash flow$56.1M-47.3%
CapEx$2.1M-27.6%
Free cash flow$54.0M-47.8%

Valuation & ratios

Valuation

See full
Market cap$326.1M-21.5%
Enterprise value$773.4M-6.0%
P/S0.4×-0.1×

Profitability

See full
Gross margin55.9%+2.4pp
FCF margin11.9%—

Returns & leverage

See full
Debt / equity1.7×+0.5×
Current ratio5.4×-0.2×

Segments

By product

See full
MCM Product sales$168.0M+188%
Commercial Product sales$52.4M-22.4%
All other revenue$13.9M-7.3%

By segment

See full
MCM Products$168.0M+188%
Commercial Products$52.4M-22.4%

Competitors

By market cap

Thermo Fisher Scientific logo
Thermo Fisher Scientific$237.15B+30.6%
Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals$79.7B+30.8%
Medline, Inc. logo
Medline, Inc.$28.2B—
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.$5.8B+89.6%
AMP
Amphastar Pharmaceuticals$1.0B-19.9%
Emergent Biosolutions logo
Emergent Biosolutions$326.1M-21.9%
SIGA Technologies logo
SIGA Technologies$214.1M-66.7%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.$156.7M-46.7%

By revenue growth

Medline, Inc. logo
Medline, Inc.+12.0%
Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals+9.3%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.+9.3%
Thermo Fisher Scientific logo
Thermo Fisher Scientific+5.6%
AMP
Amphastar Pharmaceuticals+1.0%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.-4.1%
Emergent Biosolutions logo
Emergent Biosolutions-9.6%
SIGA Technologies logo
SIGA Technologies-70.1%

By net margin

SIGA Technologies logo
SIGA Technologies43.23%+44.0pp
Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals27.86%-3.5pp
Thermo Fisher Scientific logo
Thermo Fisher Scientific15.19%0.0pp
AMP
Amphastar Pharmaceuticals10.76%-7.9pp
Emergent Biosolutions logo
Emergent Biosolutions9.62%-2.0pp
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.5.05%+4.9pp
Medline, Inc. logo
Medline, Inc.4.68%-1.7pp
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.-30.04%-9.0pp

Profile

Emergent BioSolutions is a global life sciences company that develops and manufactures preparedness and response solutions for public health threats, including chemical, biological, and opioid-related crises. The company provides a portfolio of medical countermeasures for government stockpiling alongside commercial products for community care. Their value proposition centers on protecting civilian and military populations from accidental, deliberate, and naturally occurring health emergencies.

Competitive position

A leading provider of medical countermeasures for the U.S. Strategic National Stockpile with a dominant position in the naloxone nasal spray market.

GeographiesUnited States, Canada, Australia, European Union, Singapore
Customer segmentsFederal government agencies, Public health departments, First responders, Retail consumers, Biotech innovators
Business modelB2G (Business-to-Government), B2B (Business-to-Business), Direct-to-Consumer, CDMO (Contract Development and Manufacturing)
SuppliersSingle-source raw material suppliers, Plasma collection centers, Specialized medical device component manufacturers, Contract manufacturing organizations
CustomersU.S. Department of Health and Human Services, U.S. Department of War, Retail pharmacy chains, State and local emergency services, International health ministries
CountryUnited States of America
Listed2006
Employees1.6K
CEOJoseph C. Papa Jr.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Websiteemergentbiosolutions.com
FilingsSEC EDGAR

FAQ

What is Emergent Biosolutions's market cap?
Emergent Biosolutions (EBS) has a market capitalization of $326.1M and trades on NYSE.
What is Emergent Biosolutions's revenue and profitability?
Emergent Biosolutions generated $770.2M in trailing twelve-month revenue with a net loss of $134.2M, representing a net margin of 9.6%. Gross margin stands at 55.9%, with free cash flow of $91.6M. The latest reported period is Q2 2026.
Who are Emergent Biosolutions's competitors?
Emergent Biosolutions's key competitors include SIGA Technologies, Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and others. These companies compete in similar markets and product categories.
Who does Emergent Biosolutions partner with?
Emergent Biosolutions's notable partners include Bavarian Nordic, Syngene International, Hikma Pharmaceuticals, and others.
What subsidiaries does Emergent Biosolutions have?
Emergent Biosolutions's subsidiaries include Emergent Product Development Gaithersburg Inc., Emergent Canada Inc..
Where is Emergent Biosolutions headquartered?
Emergent Biosolutions is headquartered in United States of America and employs approximately 1,600 people. It has been publicly traded since 2006.